Potential Therapeutic Applications of N-Cadherin Antagonists and Agonists

Orest W. Blaschuk*

Zonula Incorporated, Kirkland, QC, Canada

This review focuses on the cell adhesion molecule (CAM), known as neural (N)-cadherin (CDH2). The molecular basis of N-cadherin-mediated intercellular adhesion is discussed, as well as the intracellular signaling pathways regulated by this CAM. N-cadherin antagonists and agonists are then described, and several potential therapeutic applications of these intercellular adhesion modulators are considered. The usefulness of N-cadherin antagonists in treating fibrotic diseases and cancer, as well as manipulating vascular function are emphasized. Biomaterials incorporating N-cadherin modulators for tissue regeneration are also presented. N-cadherin antagonists and agonists have potential for broad utility in the treatment of numerous maladies.

Keywords: N-cadherin, adherens junctions, ADH-1, biomaterials, fibrosis, cancer, tissue regeneration, vasculature

INTRODUCTION

Cell adhesion molecules (CAMs) regulate cell adhesion, division, survival, differentiation, shape, and migration. Tissues are molded by the homotypic and heterotypic intercellular interactions of CAMs. Numerous intracellular signaling pathways are triggered when single cells adhere to one another. These activated pathways cause alterations in gene expression and subsequently impact cell behavior. CAMs are directly involved in many diseases (e.g., cancer, fibrosis). Modulators of CAM function can consequently be developed to serve as therapeutics. This review focuses on a particular CAM, known as neural (N)-cadherin (CDH2). Inhibitors (i.e., antagonists) and stimulators (i.e., agonists) of N-cadherin function are discussed, as well as their potential to serve as therapeutics for various diseases and promoters of tissue regeneration. The complexity of CAM function is revealed through the study of N-cadherin antagonist and agonist biological activity.

N-Cadherin

Cadherins are calcium-dependent cell adhesion molecules, meaning that they bind calcium and require the presence of this ion to function (Hulpiau and van Roy 2008; Blaschuk 2015; Gul et al., 2017). There are 114 different human cadherins which have been divided into 11 subfamilies (Hulpiau et al., 2013, Gul et al., 2017). They have varying tissue distributions. For example, neural (N)-cadherin is usually expressed by mesenchymal, neural, endothelial, and poorly differentiated cancer cells, whereas epithelial (E)-cadherin (CDH1) is expressed by epithelial cells and well-differentiated carcinomas (Tsuchiya et al., 2006; Mrozik et al., 2018; Derynck and Weinberg 2019). It is important to note that cells can express multiple cadherins. For example, endothelial cells express N-cadherin and vascular endothelial (VE)-cadherin (CDH5) (Colás-Algora and Millán 2019), whereas mesenchymal cells display N-cadherin and osteoblast (OB)-cadherin (CDH11) (Black et al., 2018). N-cadherin antagonists can inhibit the adhesion of cells displaying multiple cadherins (Alexander et al., 1993; Erez et al., 2004; Jiang et al., 2020).

N-cadherin is a member of the Type I cadherin subfamily. It is a single pass transmembrane glycoprotein containing extracellular (EC), transmembrane and cytoplasmic (CP) domains
(Harrison et al., 2011; Blaschuk 2015; Mrozik et al., 2018). Type I cadherin monomers exist in different states in the plasma membrane and at intercellular adhesive contacts, where they function as homophilic and heterophilic CAMs (Harrison et al., 2011; Bunse et al., 2013; Vendome et al., 2014; Blaschuk 2015; Mrozik et al., 2018). The monomers apparently interact within the plane of the plasma membrane (referred to as cis interactions) and with identical monomers on the surface of apposing cells (referred to as trans interactions). These cis and trans interactions involve the cell adhesion recognition (CAR) sequence Histidine–Alanine–Valine (His79–Ala80–Val81) which is found towards the terminus of all Type I cadherin EC1 domains. This CAR sequence was predicted to be directly involved in mediating Type I cadherin-dependent cell adhesion over 3 decades ago (Blaschuk et al., 1990a; Blaschuk et al., 1990b; Blaschuk 2015). Later studies suggested that the His79 and Val81 residues facilitate cis interactions, whereas the Ala80 residue is involved in trans interactions (Harrison et al., 2011; Bunse et al., 2013; Blaschuk 2015). The Ala80 residue is a constituent of a hydrophobic pocket into which docks a tryptophan (Trp2) found at the N-terminus of all Type I cadherin EC1 domains, thus promoting intercellular adhesion.

Only the Type I cadherins contain a hydrophobic pocket involving the CAR sequence, His-Ala-Val (HAV) and a single Trp residue at the N-terminus of their EC domains. Other cadherin family members engage using similar, but distinct mechanisms. For example, the Type II cadherins (e.g., osteoblast (OB)-cadherin) harbor two Trp residues in the second and fourth positions of their EC domains (Trp2 and Trp4) which mediate trans interactions between monomers (Patel et al., 2006; Hulpiau et al., 2013; Brasch et al., 2011, 2018). Consequently, Type II cadherins contain a larger hydrophobic binding pocket than the Type I cadherins to facilitate these interactions. It is therefore possible to design antagonists specific for Type I cadherins that do not inhibit intercellular adhesion mediated by other types of cadherins (Deveny and Blaschuk 2008, 2009).

N-Cadherin-Associated Intracellular Proteins and Their Signaling Pathways

N-cadherin-mediated cell adhesion activates many intracellular signaling pathways governing cell proliferation, apoptosis, migration, and differentiation (Kourtidis et al., 2013; Krishnamurthy and Kurzrock, 2018; Mrozik et al., 2018; Flinn et al., 2020; Young et al., 2021). The N-cadherin interactome is dependent on cell context (Li et al., 2019). For example, there are at least 350 proteins in the cardiomyocyte N-cadherin interactome. Most of these proteins are intracellular adaptor proteins. The CP domain of N-cadherin (and other Type I cadherins) binds directly to two intracellular proteins, β-catenin (Hulpiau et al., 2013; Shao et al., 2017; Adhikari et al., 2018) and p120 (Kourtidis et al., 2013; Hong et al., 2016, Li et al., 2019). These two proteins regulate the strength of cadherin-mediated intercellular adhesion, collective cell migration and gene expression (Nagafuchi and Takeichi 1988; McLachlan and Yap 2007; Nelson 2008; Mrozik et al., 2018; Young et al., 2021). They bind to different sites on the CP domain. A juxta-membrane site on the CP domain associates with p120, while a site at the carboxy-terminus of this domain binds β-catenin (Kourtidis et al., 2013; Adhikari et al., 2018; Mrozik et al., 2018).

The intracellular protein, β-catenin links Type I cadherins to the F-actin cytoskeleton via α-catenin (Hulpiau et al., 2013; Shao et al., 2017; Adhikari et al., 2018). Two actin-binding proteins that interact with α-catenin are vinculin (Bachir et al., 2017; Bays and DeMali 2017) and afadin (Li et al., 2019). All three of these actin-binding, adaptor proteins appear to be necessary for the formation of stable, cadherin-containing intercellular adhesive junctions (also see discussion below on intercellular junctions) (Valenta et al., 2012; Bays and DeMali 2017, Li et al., 2019). Vinculin is also involved in promoting cell-extracellular matrix (ECM) adhesive interactions mediated by integrins (Bachir et al., 2017; Bays and DeMali 2017). Afadin interacts directly with the cytoplasmic domain of calcium-independent, immunoglobulin-like cell adhesion molecules called nectins (Niessen 2007; Shimono et al., 2012; Huxham et al., 2021). Although nectins do not directly associate with Type I cadherins in vivo, they promote the formation of intercellular junctions (Niessen 2007).

In addition to regulating cell adhesion as a component of the plasma membrane Type I cadherin/β-catenin/α-catenin complex, β-catenin is involved in several intracellular signaling pathways, such as the canonical Wnt/β-catenin (Bachir et al., 2017; Gul et al., 2017; Krishnamurthy and Kurzrock, 2018) and Hippo/Yap (Flinn et al., 2020) pathways.

In the canonical Wnt/β-catenin pathway, β-catenin is targeted by a cytoplasmic destruction complex composed of the scaffold proteins, Axin and adenomatous polyposis coli (APC), as well as two serine/threonine kinases, casein kinase 1 (CK1) and glycogen synthase kinase 3β (GSK3β) (Jiang 2017; Santiago et al., 2017; Krishnamurthy and Kurzrock, 2018; Houschyar et al., 2019). CK1 and GSK3β phosphorylate β-catenin in the destruction complex. Phosphorylated β-catenin is then ubiquitinated and degraded.

The phosphorylation state of β-catenin is regulated by the Wnt family of secreted, cysteine-rich glycoproteins (composed of 19 members in mammals) that are known to play a pivotal role in development (Mikels and Nusse 2006; MacDonald et al., 2009; Hua et al., 2018; Krishnamurthy and Kurzrock, 2018) and cancer stem cell survival (Katoh 2017). The destruction complex is recruited to the plasma membrane upon Wnt binding to a receptor complex composed of Frizzled (Fz) and low density lipoprotein receptor-related protein 5/6 (LRP5/6) (Jiang 2017; Santiago et al., 2017; Krishnamurthy and Kurzrock, 2018; Houschyar et al., 2019). Mammals have 10 Fz receptors and two LRP5s (MacDonald et al., 2009). The Wnt receptor and destruction complexes are linked together via the intracellular protein, Dishevelled (Dsh) (Hua et al., 2018; Sharma et al., 2018; Houschyar et al., 2019). Linkage of the two complexes prevents β-catenin phosphorylation. Consequently, β-catenin accumulates in the cytoplasm and subsequently translocates to the nucleus where it is capable of acting as a co-activator of gene transcription by forming complexes with transcription factors, such as members of the LEF (lymphoid enhancer factor-1)/Tcf (T cell factor) family (LEF-1, Tcf1, Tcf3 and Tcf4), Dsh, androgen receptor, ESE1 (epithelial specific ETS1) and tribbles
pseudokinase 3 (TRIB3) (Cadigan and Waterman 2012; Santiago et al., 2017; Sharma et al., 2018; Mulholland et al., 2005; Yang and Lee 2016; Hua et al., 2019, respectively). These complexes regulate the transcription of a variety of genes (e.g., c-myc, cyclin D-1, Axin2). It is important to note that β-catenin does not bind directly to DNA (MacDonald et al., 2009; Aloysius et al., 2018). Instead, β-catenin displaces co-repressors of transcription (e.g., Tle) and forms complexes with DNA-binding transcription factors (e.g., Tcf3) at target gene promoters (Aloysius et al., 2018; Ramakrishnan et al., 2018).

Type I cadherins can also alter gene expression patterns in response to mechanical stimuli. The ability of N-cadherin to act as a mechanosensor is dependent on the canonical Wnt/β-catenin and Hippo/Yap pathways (Cosgrove et al., 2016; Flinn et al., 2020; Jiang et al., 2020; Pobbati and Hong 2020; Szulzewsky et al., 2021). The distribution of the oncoprotein, Yap within the cell can be membranous, cytoplasmic, or nuclear depending on whether it is phosphorylated. Yap (Yes-associated protein) is a transcriptional co-ordinator that binds to β-catenin and subsequently regulates gene transcription via interaction with TEAD transcription factors. Tcf may also be a component of this complex. The Hippo kinase pathway controls Yap activity. This pathway is activated by mechanical stimuli (e.g., N-cadherin-mediated cell adhesion) resulting in phosphorylation of Yap, preventing it from relocating to the nucleus, thus abrogating transcriptional activity. Further studies are required to obtain a detailed understanding of this Type I cadherin/β-catenin/Yap pathway (Jiang et al., 2020).

In summary, cellular β-catenin exists in three pools: 1) plasma membrane; 2) cytoplasmic; and 3) nuclear. The cellular localization of β-catenin is dependent on its state of phosphorylation which is indirectly influenced by Wnt binding to a heterodimeric receptor complex composed of Fz and LRP5/6. The Hippo/Yap pathway may impact these pools.

Similar to β-catenin, the intracellular, Type I cadherin-binding protein, p120 also exists in three cellular pools (Keil et al., 2013; Kourtidis et al., 2013; Hong et al., 2016; Gul et al., 2017). It is a member of the armadillo (ARM) family of cadherin-binding proteins which includes β-catenin (Hulpiau et al., 2013; Keil et al., 2013; Kourtidis et al., 2013; Gul et al., 2017). Members of this family all possess variable numbers of tandem repeats (termed ARM repeats), each containing approximately 40 amino acids (Shapiro and Weis 2009; Hulpiau et al., 2013; Keil et al., 2013). The ARM repeats mediate protein-protein interactions (e.g., p120 binding to the Type I cadherin CP domain).

N-cadherin clustering and function are controlled by p120 (Taulet et al., 2009; Hong et al., 2016; Mrozik et al., 2018; Gritsenko et al., 2020). In addition, p120 regulates N-cadherin endocytosis and degradation. The molecular mechanisms regulating formation of N-cadherin-p120 heterodimers are not fully understood, but changes in the phosphorylation of p120 have been reported to modulate the interaction between this intracellular protein and Type I cadherins (Hong et al., 2016; Kota et al., 2019). Studies have shown that phosphorylation of selected tyrosine residues on p120 correlates with an increased binding affinity for Type I cadherins.

In addition to binding Type I cadherins, p120 also interacts with Rho GTPase family members, thereby regulating their activity and influencing actin cytoskeletal dynamics (Menke and Giehl 2012; Kourtidis et al., 2013; Kota et al., 2019; Gritsenko et al., 2020). Collective cell migration is therefore modulated by Type I cadherin-mediated intercellular adhesion (Gritsenko et al., 2020).

The serine/threonine kinase CK1ε phosphorylates p120 in response to stimulation by Wnt (see preceding discussion of the Wnt/β-catenin signaling pathway) (Jiang 2017; Pierre et al., 2019). Phosphorylated p120 translocates to the nucleus where it interacts with Kaiso, a repressor of gene transcription. Notably, Kaiso represses the transcription of genes encoding epithelial (E)-cadherin, β-catenin, Wnt11, matrilysin, miR-200 and cyclin D1. Paradoxically, this transcription factor is also capable of activating gene transcription. The switch from repressor to activator is currently thought to be dependent on the state of Kaiso SUMOylation. SUMOylated, Kaiso is believed to act as an activator, whereas deSUMOylated Kaiso functions as a repressor.

Kaiso is a positive regulator of c-myc, BRCA1, TGFβ1 and two receptor gene expression (Pierre et al., 2019). BRCA1 is involved in DNA repair of double-strand breaks (Macedo et al., 2019), whereas c-myc is a transcription factor regulating many biological processes, such as cell proliferation, genomic integrity, angiogenesis, metabolism and apoptosis (Elbadawy et al., 2019). TGFβ (the ligand for TGFβ1 and two receptors) is a key regulator of the biological process by which epithelial cells undergo morphogenetic changes, lose their apico-basal polarity, and enter a mesenchymal state where they are migratory and invasive (Nieto et al., 2016). This process is known as the epithelial-mesenchymal transition (EMT) and occurs during embryogenesis and oncogenesis. Notably, E- and N-cadherin are markers for epithelial and mesenchymal cell states, respectively (Derynck and Weinberg 2019). TGFβ signaling ultimately results in the activation of three families of transcription factors (ZEB, Snail and Twist) that down-regulate expression of epithelial genes such as E-cadherin and up-regulate expression of mesenchymal genes such as N-cadherin (Nieto et al., 2016; Goossens et al., 2017; Derynck and Weinberg 2019; Fardi et al., 2019). In summary, p120 influences the process of EMT by directly engaging with cadherins, regulating cytoskeletal dynamics and stimulating mesenchymal gene expression.

Intercellular adhesion mediated by N-cadherin triggers multiple intracellular signaling pathways resulting in profound morphogenetic changes in the adherent cells. The effects of N-cadherin antagonists and agonists on cells will predictably be complex and dependent on cell type.

**Intercellular Junctions Containing N-Cadherin**

Intercellular junctions are protein-rich, lipid-poor plasma membrane domains formed between apposed adherent cells. They are complex, multi-protein structures that directly promote cell-cell adhesion and transduce stimuli from the external environment into the cell (Erez et al., 2005; Charras...
Adherens junctions (AJs) are a diverse group of intercellular junctions (Erez et al., 2005; Franke et al., 2009, Li et al., 2019). They contain Type I cadherins (e.g., N-cadherin) and various other proteins (depending on the cell type) in their membranous domain, as well as β-catenin, a-catenin, p120 and other proteins (depending on the cell type) in a sub-membranous, electron dense, cytoplasmic plaque attached to microfilaments of the cytoskeleton. AJs can be formed by homotypic and heterotypic cell aggregates (Volk and Geiger 1986a; Volk et al., 1987; Miyatani et al., 1989; Mora et al., 2012). Heterotypic cell contacts contain AJs with either one, or two different Type I cadherins, whereas homotypic cell AJs contain one.

There are many morphologically distinct types of intercellular junctions containing N-cadherin (Franke et al., 2009; Donke et al., 2014; Vite and Radice 2014; Mizutani et al., 2021). The size and shape of Type I cadherin-containing intercellular junctions is likely regulated by p120 interacting with Rho GTPases, thereby influencing actin dynamics and cadherin clustering (Anastasiadis and Reynolds 2001; Ting et al., 2012; Kourtidis et al., 2013; Mrozik et al., 2018; Gritsenko et al., 2020). These junctions usually contain other CAMs in addition to N-cadherin (e.g., nectins, desmogleins) and associated intracellular proteins (e.g., afadin, catenins, protein tyrosine kinases and phosphatases), as well as growth factor receptors (e.g. FGF receptor) (Takai and Nakanishi 2003; Erez et al., 2005; McLachlan and Yap 2007; Niessen 2007; Franke et al., 2009; Shimono et al., 2012; Mrozik et al., 2018, Li et al., 2019). The diverse intercellular junctions enable adult tissues to maintain their integrity in the absence of N-cadherin activity. Indeed, antagonists of N-cadherin are not toxic in humans and other animals (Blaschuk 2015).

**Biological Properties of N-Cadherin Antagonists**

Studies utilizing N-cadherin antagonists have been ongoing for over 3 decades (Blaschuk 2015). The responses of different cell types to these antagonists are diverse, as the N-cadherin interactome is large and subject to manipulation by a variety of stimuli (e.g., growth factors). The composition of CAMs displayed by a given cell type is also variant, thereby resulting in differential effects of N-cadherin antagonists on intercellular adhesion, and the intracellular signaling pathways associated with this process.

The first N-cadherin antagonists were monoclonal antibodies (Mabs) capable of inhibiting cell-cell adhesion (Volk and Geiger 1986b; Hatta and Takeichi 1986b; Blaschuk 2015). Studies have subsequently shown that Mabs directed against the N-cadherin EC domain can inhibit cancer cell proliferation and invasiveness in vitro and in vivo (Tanaka et al., 2010; Mrozik et al., 2018). These and other observations have given rise to the hypothesis that N-cadherin antagonists may be useful anti-cancer drugs (see next section). Furthermore, Mabs directed against N-cadherin block the differentiation of cells, such as osteoblasts (Hay et al., 2000; Marie 2002) and mesenchymal stem cells (MSC) (Oberlender and Tuan 1994; Tuan 2003) underlining the ability of CAMs to modulate gene expression.

Short, synthetic linear peptides containing the Type I cadherin CAR sequence, His-Ala-Val (AHAYSE and LRAHAVDVNG) were then shown to be capable of disrupting N-cadherin-mediated neurite outgrowth on astrocytes (Blaschuk et al., 1999b; Chuah et al., 1991). Other papers followed demonstrating the ability of synthetic peptides harboring the CAR sequence to inhibit a variety of N-cadherin-mediated processes, such as myoblast fusion (Mege et al., 1992) and bone marrow osteoprogenitor stromal cell adhesion (Cheng et al., 1998).

Phage display technology was used to identify additional amino acid sequences capable of binding to N-cadherin (Devemy and Blaschuk 2008; Blaschuk and Devemy 2013). All the peptides (12-mers) that were identified harbored a Trp residue in the second position from the N-terminus (e.g., SWTLYTPSGQSK). Similarly, all type I cadherin ectodomains harbor a Trp residue in the second position from the N-terminus. As previously discussed, Type I cadherin-mediated intercellular adhesion involves the docking of a cadherin monomer Trp2 residue into a hydrophobic pocket (containing the HAV sequence) within a cadherin monomer ectodomain on the surface of an opposing cell. The peptide SWTLYTPSGQSK inhibited N-cadherin-dependent endothelial cell adhesion and tube formation in vitro.

A family of synthetic cyclic peptides containing the cadherin CAR sequence HAV was first described by Blaschuk and Gour (Blaschuk and Gour 2000). The most utilized N-cadherin antagonist of this family is the synthetic cyclic peptide CHAVC (also known as ADH-1 and Exherin) (Blaschuk 2015). This cyclic peptide has been shown to affect the N-cadherin-mediated adhesion, migration, proliferation, and apoptosis of a variety of cell types in vitro. For example, ADH-1 inhibits N-cadherin-dependent neurite outgrowth on fibroblasts (Williams et al., 2000), as well as Schwann cell (Wilby et al., 1999) and oligodendrocyte (Schnädelbach et al., 2000) adhesion to, and migration on astrocytes. ADH-1 has also been shown to inhibit bovine capillary endothelial cell (BCEC), murine capillary endothelial cell (MCEC) (Erez et al., 2004), granulosa cell (Makriyanakis et al., 1999) and skin fibroblast adhesion (Jiang et al., 2020).

The loss of N-cadherin-mediated intercellular adhesion can lead to activation of apoptosis (Mrozik et al., 2018). For example, ADH-1 stimulates EC (Erez et al., 2004), granulosa (Makriyanakis et al., 1999), neuroblastoma (Lammens et al., 2012) and vascular smooth muscle cell (VSMC) (Lyon et al., 2010) apoptosis in vitro. This effect of ADH-1 is thought to involve suppression of the phosphatidylinositol-3-kinase (PI3K)/Akt kinase/Bad pathway (Mrozik et al., 2018). The precise molecular mechanisms by which N-cadherin antagonists induce apoptosis remain to be clarified. In particular, the effects of these antagonists on the well-established association of the FGF receptor (the membrane anchor of the PI3K/Akt/Bad pathway) with N-cadherin in the plane of the plasma membrane (Nguyen and Mege 2016; Kon et al., 2019; Quintanal-Villalonga et al., 2020) needs to be thoroughly examined.
ADH-1 has been shown to inhibit cell migration. For example, fibroblasts present in the subcutaneous fascia of mouse skin form migratory, N-cadherin-dependent cell collectives (connected by AJs) in response to injury (i.e., deep skin cuts). ADH-1 prevents the formation of these cell collectives and their migratory behavior (Jiang et al., 2020). This N-cadherin antagonist is thought to influence formation and migration of cell collectives by indirectly regulating p120/Rho GTPase activity (Gritsenko et al., 2020).

ADH-1 inhibits tumor growth in pre-clinical animal models (Shintani et al., 2008; Mrozik et al., 2018). It has also been examined in phase I clinical trials for the treatment of solid cancers (Beasley et al., 2009; Perotti et al., 2009). ADH-1 was well-tolerated and showed potential as an antitumor drug. This is the only N-cadherin antagonist to enter clinical trials to date. The use of ADH-1 as an anti-cancer therapeutic is discussed in more detail below.

Numerous non-peptidyl peptidomimetics of ADH-1 have been discovered, but the biological properties of only one (LCRF-0006, 5-[(3,4-dichlorobenzyl)sulfonyl]-4H-1,2,4-triazol-3-amine) have been extensively studied (Gour et al., 2007; Mrozik et al., 2020). The N-cadherin antagonist LCRF-0006 inhibits neurite outgrowth and bone marrow endothelial cell (BMEC) adhesion in vitro. LCRF-0006 is also capable of disrupting BMEC monolayers, preventing endothelial tube formation in Matrigel, and disrupting mature endothelial tubes (Mrozik et al., 2020). LCRF-0006 did not cause BMEC apoptosis, in contrast to ADH-1. This discrepancy could be caused by the different types of ECs that were used to evaluate the apoptotic effects of the N-cadherin antagonists (BCEC and MCEC, as opposed to BMEC). This observation indicates that not all types of ECs respond similarly to N-cadherin antagonists.

LCRF-0006 is well-tolerated by mice. Treatment of mice with LCRF-0006 does not have obvious effects on bone blood vessel morphology, hematopoiesis, and N-cadherin expressing mesenchymal stromal cells, osteoblasts, and osteoprogenitors (Mrozik et al., 2020). Significantly, this N-cadherin antagonist did increase multiple myeloma (MM) tumor vascular permeability, suggesting that N-cadherin antagonists could facilitate drug delivery. The effects of N-cadherin antagonists on vasculature will be discussed further in a following section.

Non-peptidyl peptidomimetics of the Trp-containing, N-cadherin amino-terminus have been discovered and shown to inhibit N-cadherin-mediated intercellular adhesion (Vaisburg and Blaschuk 2019). One of these N-cadherin antagonists, designated compound 15, (S)-1-(3,4-Dichlorophenox)-3-(4-((S)-2-hydroxy-3-(4-methoxyphenox)propylamino)piperidin-1-yl)propan-2-ol causes Panc 1 human pancreatic cancer cell, U87MG human glioblastoma multiforme cell (GBM), fibroblast, cancer-associated fibroblast (CAF) and fibroblast-like synoviocyte (FLS) death (Blaschuk 2020; Smits et al., 2020). Normal human astrocytes are not affected by this compound, indicating that not all cell types are killed by this N-cadherin antagonist (Smits et al., 2020). Compound 15 was found to be well-tolerated by mice (Blaschuk 2020).

The preceding discussion indicates that N-cadherin antagonists have a wide variety of therapeutic applications. Some of these will be considered in the next section.

PROSPECTIVE THERAPEUTIC APPLICATIONS OF N-CADHERIN ANTAGONISTS

N-Cadherin Antagonists for the Treatment of Fibroblast-Based Diseases

Fibroblasts are a heterogenous population of cells with different subtypes expressing variable levels of N-cadherin (Angelucci et al., 2012; Janson et al., 2013; Konstantinova and Pearce 2015; Jiang et al., 2020; Ascensión et al., 2021; Plikus et al., 2021). Inhibition of N-cadherin function has been shown to decrease fibroblast adhesion, migration, proliferation, survival, and differentiation (Konstantinova and Pearce 2015; Black et al., 2018; Blaschuk 2020; Jiang et al., 2020), as well as collagen synthesis and secretion by these cells (Konstantinova and Pearce 2015).

The excessive deposition of ECM proteins (e.g., collagen and fibronectin) by activated fibroblasts and myofibroblasts results in thickening and hardening of tissues (i.e., fibrosis) (Knuppel et al., 2017; Huang et al., 2021; Plikus et al., 2021). Tissue fibrosis is involved in the genesis of many diseases. For example, idiopathic pulmonary fibrosis (IPF) is believed to be initiated by damage to the lung alveolar epithelium from chronic inflammatory processes, infections, and environmental agents (Knuppel et al., 2017; Black et al., 2018; Chanda et al., 2019). Immune cells (e.g., macrophages) are recruited to the site of epithelial damage. They secrete TGF-β (a key, but not the only, mediator of fibrosis) which stimulates fibroblasts to differentiate into myofibroblasts. These cells proliferate and secrete collagen, which accumulates in the lungs as disorganized fibrils causing scar formation and loss of tissue elasticity. Inhibition of fibroblast function, differentiation and survival utilizing N-cadherin antagonists may thus be an effective anti-fibrotic strategy for treating pulmonary diseases such as IPF (Konstantinova and Pearce 2015; Black et al., 2018; Blaschuk 2020).

Fibroblasts are also intimately involved in the formation of scars resulting from the repair of skin wounds (Correa-Gallegos et al., 2019; Jiang et al., 2020; Jiang et al., 2021). Scar formation involves a subpopulation of fibroblasts (designated engrafted-past fibroblasts) residing in the subcutaneous fascia of the skin which are activated upon injury. These cells up-regulate N-cadherin, aggregate, and migrate as cell collectives into the wound where they deposit collagen giving rise to scars (Jiang et al., 2020). The N-cadherin antagonist ADH-1 inhibits these processes. Based on these observations, N-cadherin antagonists could be envisioned as therapeutics for the reduction of scar formation. The hypothesis has been proposed that fibroblast aggregation and migration is a general response to tissue injury. This hypothesis emphasizes the need to thoroughly investigate the biological effects of N-cadherin antagonists.

The microenvironment of tumors contains a heterogenous population of cells that are intimately associated, and reciprocally....
 communicating with cancer cells, called cancer-associated fibroblasts (CAFs) (Öhlund et al., 2017; Nurmik et al., 2020; Sahai et al., 2020). These cells express N-cadherin (Angelucci et al., 2012; Blaschuk 2020). Tumors can be categorized based on the number of CAFs residing in their microenvironment (Bagaev et al., 2021). Solid tumors (e.g., pancreatic ductal adenocarcinoma) become fibrotic due to the large numbers of CAFs in their microenvironment secreting ECM components such as collagen (Öhlund et al., 2017; Winkler et al., 2020). CAFs are thus capable of regulating the immune response to a tumor by modulating direct interactions between T cells and cancer cells. Similarly, the ability of small molecules (e.g., anti-cancer drugs) and biologics (e.g., anti-tumor monoclonal antibodies) to penetrate the tumor and bind cancer cells is limited by permeability barriers arising from CAFs and their associated ECM components within the stroma (Olive et al., 2009; Joyce and Fearon 2015; Olive 2015). As N-cadherin antagonists (e.g., compound 15) block CAF adhesion and decrease their viability (Blaschuk 2020), they could be used to remodel fibrotic tumors, thus facilitating T cell-cancer cell interactions and drug delivery into tumors.

### N-Cadherin Antagonists as Modulators of Blood Vessel Formation, Stability, and Function

There are two types of mural cells comprising blood vessels: pericytes and VSMC (Smyth et al., 2018). The latter cell type is only present in large blood vessels (i.e., arteries, veins) (Smyth et al., 2018; Caporarello et al., 2019). The assembly and maintenance of a functional vasculature is dependent on N-cadherin-mediated EC-EC and EC-mural cell (e.g., pericyte) adhesion (Gerhardt et al., 2000; Deveny and Blaschuk 2008; Blaschuk and Deveny 2009; Caporarello et al., 2019; Kruse et al., 2019; Mrozik et al., 2020; Perrot et al., 2020). N-cadherin antagonists (e.g., ADH-1, LCRF-0006, anti-N-cadherin antibodies) can therefore be used to manipulate the vasculature, as they disrupt EC-EC and EC-pericyte interactions (Alexander et al., 1993; Blaschuk and Rowlands 2000; Gerhardt et al., 2000; Deveny and Blaschuk 2008; Caporarello et al., 2019; Mrozik et al., 2020).

Pericytes have emerged as key regulators of blood flow and vessel permeability (Gerhardt et al., 2000; Gerhardt and Betsholtz 2003; Blaschuk and Deveny 2009; Caruso et al., 2009; Caporarello et al., 2019; Kruse et al., 2019; Li et al., 2019; Perrot et al., 2020; Alarcon-Martinez et al., 2021). They stabilize blood vessels by adhering to ECs via AJJs and secreting components (e.g., collagen) of the basement membrane. Furthermore, pericytes are contractile cells that ensheath ECs, thus regulating blood flow (Caporarello et al., 2019; Perrot et al., 2020; Alarcon-Martinez et al., 2021). Blood vessels deficient in pericytes (e.g., tumor microvessels) exhibit poor blood flow, increased permeability, and an abnormal basement membrane (Jain 2005; Blaschuk and Deveny 2009; Li et al., 2019; Mrozik et al., 2020) making them particularly susceptible to disruption by N-cadherin antagonists (Blaschuk and Rowslands 2000, 2006). These antagonists can be considered as vasculature-targeting agents for use in the treatment of cancer.

The N-cadherin antagonist LCRF-0006 has been shown to disrupt EC adhesion and tube formation in vitro and increase tumor blood vessel permeability in vivo (Mrozik et al., 2020). This antagonist enhanced the potency of bortezomib (a drug used to treat multiple myeloma) in a mouse model of multiple myeloma. These observations suggest that N-cadherin antagonists can be used to promote drug penetration into tumors by lowering permeability barriers.

In addition to being modulators of blood vessel integrity (i.e., vasculature-targeting agents), N-cadherin antagonists can also inhibit blood vessel formation (i.e., vasculogenesis and angiogenesis) by preventing EC-EC and EC-pericyte adhesion (Radice et al., 1997; Blaschuk and Rowlands 2000, 2006; Gerhardt et al., 2000; Blaschuk et al., 2003; Paik et al., 2004). Studies have shown that tumors require an adequate blood supply to grow (Jain 2005; Li et al., 2018, Li et al., 2019). N-cadherin antagonists can conceivably act as anti-angiogenic agents to inhibit tumor growth. They might also be effective in treating a variety of angiogenic-dependent diseases (e.g., age-related macular degeneration, obesity) (Fallah et al., 2019).

A difficult concept to grasp is that N-cadherin antagonists can have both anti- and pro-angiogenic activities by virtue of their ability to regulate EC-pericyte adhesion (Gerhardt and Betsholtz 2003; Perrot et al., 2020; Payne et al., 2021). The process of angiogenesis has several distinct phases (Li et al., 2019; Payne et al., 2021). The first phase involves disengagement of the pericytes from the endothelium of mature microvessels. This process is facilitated by N-cadherin antagonists (Gerhardt et al., 2000; Gerhardt and Betsholtz 2003; Paik et al., 2004; Perrot et al.,

### Table 1: N-Cadherin Antagonists and Agonists

| Compound name            | Type                     | Structure                      | N-cadherin modulating activity | Stage of development | Therapeutic potential         |
|--------------------------|--------------------------|--------------------------------|--------------------------------|----------------------|--------------------------------|
| HAV-containing peptide   | linear peptide           | LRAHAVDONG                     | antagonist                     | discovery            | in vitro proof of concept      |
| Trip-containing peptide  | linear peptide           | SWTLYTPSGQSK                   | antagonist                     | discovery            | in vitro proof of concept      |
| ADH-1 (Exherin)          | cyclic peptide           | CHAVC                          | antagonist                     | clinical (Phase 2)   | cancer                         |
| LCRF-0006                | small molecule           | Triazol                        | antagonist                     | pre-clinical         | drug delivery                  |
| Compound 15              | small molecule           | Pipepen-4-amine                | antagonist                     | pre-clinical         | pancreatic cancer              |
| HAV dimeric              | cyclic dimeric           | CHAVDINGHAVDIC                 | agonist                        | pre-clinical         | neural regeneration            |
| HAV-biomaterial          | linear peptide conjugated to hydrogel | HAV peptide-hydrogel | agonist                        | pre-clinical         | cartilage regeneration         |

*aSee text for details.*
Angiogenesis begins in the unconstricted (Freitas-Andrade et al., 2020; Di et al., 2021). Angiogenesis begins in the peri-infarct region rapidly after the stroke. N-cadherin antagonists could hasten the healing process by stimulating microvessel formation and neurogenesis. In addition, these antagonists could facilitate blood flow into the region by loosening adhesion between contracted pericytes and the endothelium thus allowing microvessels to become unconstricted (Freitas-Andrade et al., 2020; Di et al., 2021). Reducing pericyte contraction and thereby rapidly stimulating blood flow after ischemic stroke may lessen damage to the brain. Uncoupling of microvascular pericyte-EC adhesion has also been shown to give rise to scar-forming stromal cells (i.e., fibroblasts) at sites of damage in the central nervous system (CNS) (Dias et al., 2021; Rentsch and Rust 2022). Specifically, a subpopulation of pericytes (termed type A pericytes) residing in the mammalian CNS vasculature disengages from the endothelium after either brain or spinal cord injury, proliferates, differentiates into scar-forming stromal cells (i.e., fibroblasts secreting collagen 1 and fibronectin), aggregates and migrates into the infarct. N-cadherin antagonists may prevent scar formation in the CNS lesions by inhibiting some, or all these processes. This hypothesis deserves examination.

VSMC proliferation and migration contributes to restenosis (i.e., reduction in blood vessel lumen diameter) after angioplasty, stent placement, bypass vein graft surgery and atherogenesis (Lyon et al., 2010; Wadey et al., 2018; Aoki and Tanabe 2021). N-cadherin and the β-catenin/Wnt signaling pathway have been shown to be directly involved in regulating VSMC proliferation and migration (Lyon et al., 2010; Wadey et al., 2018). The N-cadherin antagonist, ADH-1 is capable of inhibiting VSMC migration and promotes apoptosis of these cells (Lyon et al., 2010). N-cadherin antagonists may therefore be useful inhibitors of restenosis and could be incorporated into drug-eluting stents. The multimodal actions of N-cadherin antagonists on blood vessels necessitates a careful evaluation of their biological activities on both normal vasculature, and that present in tumors and damaged tissues. Studies clearly indicate that these antagonists have different effects on normal, as opposed to tumor blood vessels. Normal vasculature does not appear to be severely affected by N-cadherin antagonists, whereas abnormal vasculature deficient in pericytes is sensitive to these agents (Beasley et al., 2009; Perotti et al., 2009; Tanaka et al., 2010; Mrozik et al., 2020). The effect of N-cadherin antagonists will likely be influenced by many variables including: the repertoire of CAMs (e.g., integrins, nectins) expressed by a particular cell type, method of administration, dosing schedule, tumor size and type, pericyte coverage of the endothelium, and growth factor (e.g., VEGF) levels. It is also important to consider the type of antagonist to be used for a particular application. Small molecule antagonists will have different pharmacokinetics than anti-N-cadherin antibodies (e.g., dissimilar half-lives in the blood). Judicious use of N-cadherin antagonists will be required to achieve optimal effects on the vasculature.

N-Cadherin Antagonists as Cancer Therapeutics

The effects of N-cadherin antagonists on tumors are likely to be multifaceted and dependent on tumor type. N-cadherin antagonists can conceivably affect the tumor’s cancer cells, CAFs, pericytes and ECs, as they all express N-cadherin. The cellular compositions of solid (e.g., pancreatic ductal adenocarcinoma) and liquid (e.g., multiple myeloma) tumors are vastly different (Olive 2015; Mrozik et al., 2018; Li et al., 2019; Bagaev et al., 2021). N-cadherin antagonists would consequently be expected to have significantly different biological effects on solid and liquid tumors.

Aberrant N-cadherin expression has been observed in many cancer cell types (Nagi et al., 2005; Gravdal et al., 2007; Mrozik et al., 2018; Cao et al., 2019; Derynck and Weinberg 2019). N-cadherin is involved in regulating cancer cell adhesion, proliferation, survival, invasiveness, and metastasis. These observations suggest that N-cadherin antagonists could serve as potent anti-cancer drugs due to their ability to affect many of the steps necessary for tumor progression.

The biological effects of N-cadherin antagonists on tumors have been extensively studied in a variety of preclinical animal models (Shintani et al., 2008; Tanaka et al., 2010; Blaschuk 2015; Mrozik et al., 2018, 2020; Sun et al., 2021). These antagonists are capable of decreasing the growth of various cancer types in mice (e.g., pancreatic and prostate tumors). N-cadherin antagonists have also been shown to enhance the effectiveness of anti-cancer drugs (e.g., bortezomib) by increasing tumor blood vessel permeability (Mrozik et al., 2020). This observation suggests that N-cadherin antagonists would be useful in combination therapy to increase the penetration of drugs into tumors.

In addition, N-cadherin antagonists can potentiate the immune response to tumors by regulating programmed cell death ligand 1 (PD-L1) levels (Sun et al., 2021). PD-L1 is expressed on the surface of cancer cells, where it can interact with the receptor, PD-1 on the T cell membrane to suppress the immune response against tumors (Dong et al., 2018; Ribas and Wolchok 2018). ADH-1 is capable of down-regulating PD-L1 expression, thus facilitating T cell-mediated killing of cancer cells (Sun et al., 2021). The usefulness of N-cadherin antagonist in immuno-oncologic therapies has not been fully appreciated to date.

N-cadherin has recently emerged as a potential therapeutic target for three types of brain cancers: meningioma (Magill et al., 2020), neuroblastoma (Lammens et al., 2012) and glioblastoma multiforme (Smits et al., 2020). There are currently no adequate treatments for these cancers. N-cadherin antagonists have the potential to fulfill the need for new brain cancer therapeutics.

A particularly noteworthy study demonstrated that AJs containing the N-cadherin/β-catenin/p120 complex are necessary for the formation of migrating glioma cell collectives infiltrating the brain (Gritsenko et al., 2020). Down regulation of
either these proteins prevented glioblastoma cell adhesion and formation of cell collectives in vitro. Cell proliferation was also decreased by the down-regulation of p120 (N-cadherin and β-catenin were not examined). These observations are in concordance with those concerning the importance of N-cadherin in facilitating the collective migration of fibroblasts during the process of scar formation.

Studies have shown that the N-cadherin antagonists ADH-1 and compound 15 decrease glioblastoma and neuroblastoma cell viability in vitro (Smits et al., 2020; Lammens et al., 2012, respectively). ADH-1 has also been shown to inhibit the proliferation and tumorigenesis of meningioma cells in co-cultures with human cerebral organoids (Magill et al., 2020). Collectively, these observations indicate that N-cadherin antagonists may have clinical utility for the treatment of brain cancers.

As discussed previously, ADH-1 is the only N-cadherin antagonist that has entered clinical trials (Beasley et al., 2009; Perrotti et al., 2009; Yarom et al., 2011, 2013). ADH-1 was well-tolerated, altered tumor vascular permeability and decreased tumor growth in some patients. For example, a female with an N-cadherin positive metastatic adenocortical carcinoma was treated with a single dose of ADH-1 at 150 mg/mm2 (Yarom et al., 2011). This treatment caused transient normalization of plasma cortisol, tumor necrosis, and a reduction in tumor perfusion. In another Phase clinical study, two patients with ovarian cancer exhibited prolonged disease stabilization and one patient with fallopian tube carcinoma had a mixed response to treatment with ADH-1 (Perrotti et al., 2009). These results indicate that N-cadherin antagonists might be useful in the treatment of gynaecological cancers. The results obtained from clinical trials have encouraged the development of more potent, small molecule, N-cadherin antagonists (e.g., compound 15). These new antagonists have yet to be evaluated for their activity against tumors in preclinical and clinical studies.

Biological Properties of N-Cadherin Agonists

Most N-cadherin agonists contain the N-cadherin CAR sequence, HAV (Utton et al., 2001; Williams et al., 2002; Skaper et al., 2004; Feng et al., 2020; Zhang et al., 2020; Dieterle et al., 2021). For example, the soluble cyclic peptide N-Ac-CHAVDINGHAVDIC-NH2 has been shown to be such an agonist (Williams et al., 2002; Skaper et al., 2004). This peptide can stimulate neurite outgrowth in vitro, a process known to be dependent on N-cadherin. The cyclic peptide is thought to cause dimerization of N-cadherin monomers within the plane of the plasma membrane, thus activating the associated FGF receptor signaling pathway.

 Peptides containing the HAV sequence can be attached to scaffolds (e.g., methacrylated hyaluronic acid hydrogels) to form biomaterials that are able to act as N-cadherin agonists in vitro and in vivo (Bian et al., 2013; Feng et al., 2020; Zhang et al., 2020; Dieterle et al., 2021; Kaur and Roy 2021; Zhu et al., 2021). For example, human MSC displaying N-cadherin can be induced to enter chondrogenesis by culturing them in HAV-containing hydrogels (Li et al., 2017). The canonical Wnt/β-catenin signaling pathway is suppressed in these cultures causing a reduction of β-catenin levels in the nucleus (see preceding discussion of this pathway). In another example, a hydrogel composed of an HAV-containing peptide covalently tethered to polyethylene glycol dimethacrylate was shown to promote human neural stem cell differentiation, neurite outgrowth, and survival in vitro (Kaur and Roy 2021). These two examples demonstrate the ability of HAV-containing biomaterials to act as N-cadherin agonists and direct stem cell differentiation.

Prospective Therapeutic Applications of N-Cadherin Agonists

The observation that soluble N-cadherin agonists and HAV-containing peptides tethered to hydrogels can promote certain steps necessary for neural regeneration suggests that they have the potential to serve as therapeutics for CNS and peripheral nervous system injuries and diseases. In particular, hydrogels with HAV-conjugated peptides have been shown to stimulate neurogenesis, axonal sprouting, and neural plasticity (Lim et al., 2017; Katoh et al., 2019; Kaur and Roy 2021). Biomaterials composed of HAV peptide-conjugated hydrogels have also shown promise in stimulating the regeneration of cartilage (Feng et al., 2020; Zhang et al., 2020). For example, bone marrow MSCs encapsulated in such hydrogels are capable of promoting cartilage formation in rabbit knee osteochondral defects (Feng et al., 2020). Implanting or injecting stem cells (e.g., MSCs) encapsulated in appropriately designed biomaterials (e.g., those conjugated with HAV-containing peptides) into damaged tissue represents a new approach to treating a variety of injuries.

Summary and Future Directions

A number of N-cadherin agonists and antagonists have been discovered over the last 3 decades, but only one antagonist (the cyclic peptide CHAVC, designated ADH-1) has entered human clinical trials (Table 1). It was well tolerated and showed promise as an anti-cancer drug. More potent, orally available small molecules have recently been described (i.e., compound 15 and other derivatives of piperidin-4 amine). Their activities remain to be extensively evaluated in animal models for cancer and other maladies.

N-cadherin agonists (HAV-containing peptides conjugated to hydrogels) have demonstrated the ability to influence stem cell differentiation in vitro and in vivo. These biomaterials have shown promise for use in tissue regeneration and should be subjected to further studies.

A major theme that has emerged concerns the ability of N-cadherin antagonists to regulate fibrosis by virtue of their ability to inhibit fibroblast adhesion and collagen production. Preclinical studies have shown that ADH-1 can prevent fibroblast-dependent scar tissue formation in the skin. N-cadherin antagonists thus have the potential to serve as therapeutics for many fibrosis-dependent diseases.

N-cadherin agonists and antagonists will likely need to be combined with other agents (e.g., growth factors. T cells, anticancer drugs, monoclonal antibodies) to achieve maximum
efficacy in the treatment of various maladies. Combination therapies involving N-cadherin function modulators remain to be extensively investigated.

**REFERENCES**

Adhikari, S., Moran, J., Weddle, C., and Hinczewski, M. (2018). Unraveling the Mechanism of the Cadherin-Catenin-Actin Catch Bond. PLoS Comput. Biol. 14, e1006399. doi:10.1371/journal.pcbi.1006399

Alcaron-Martinez, L., Yemisci, M., and Dalkara, T. (2021). Pericyte Morphology and Function. Histol. Histopathol. 36, 633–643. doi:10.14670/HH-18-314

Alexander, J. S., Blaschuk, O. W., and Haselton, F. R. (1993). An N-cadherin-like Protein Contributes to Solute Barrier Maintenance in Cultured Endothelium. J. Cel. Physiol. 156, 610–618. doi:10.1002/jcp.1041560321

Aloysius, A., DasGupta, R., and Dhawan, J. (2018). The Transcription Factor Lef1 Switches Partners from β-catenin to Smad3 during Muscle Stem Cell Quiescence. Sci. Signal. 11, eaax3000. doi:10.1126/scisignal.aax3000

Anastasiadis, P. Z., and Reynolds, A. B. (2001). Regulation of Rho GTPases by PI2-Catenin. Curr. Opin. Cel. Biol. 13, 604–610. doi:10.1016/s0955-0674(00)00258-1

Angelucci, C., Mauclucci, G., Lama, G., Proietti, G., Colabianchi, A., Papi, M., et al. (2012). Epithelial-stromal interactions in Human Breast Cancer: Effects on Adhesion, Plasma Membrane Fluidity and Migration Speed and Directness. PLoS One 7, e50084. doi:10.1371/journal.pone.0050084

Aoki, J., and Tanabe, K. (2021). Mechanisms of Drug-Eluting Stent Restenosis. Cardiovasc. Interv. Ther. 36, 23–29. doi:10.1007/s12928-020-00734-7

Ascensión, A. M., Fuertes-Álvarez, S., Ibañez-Solé, O., Izeta, A., and Araúzo-Bravo, M. J. (2021). Human Dermal Fibroblast Subpopulations Are Conserved across Single-Cell RNA Sequencing Studies. J. Invest. Dermatol. 141, 1735–1744. e35. doi:10.1016/j.jid.2020.11.028

Bachir, A. I., Horwitz, A. R., Nelson, W. J., and Bianchini, J. M. (2017). Actin-Based Adhesion Modules Identify Speciﬁc Protein Complexes Underlying Cell-Adhesive Behavior. Cell Rep. 23, 1840–1852. doi:10.1016/j.celrep.2018.04.012

Bunse, S., Garg, S., Junek, S., Vogel, D., Ansari, N., Stelzer, E. H. K., et al. (2013). Role of N-Cadherin Cis and Trans Interfaces in the Dynamics of Adherens Junctions in Living Cells. PLoS ONE 8, e81517. doi:10.1371/journal.pone.0081517

Cadigan, K. M., and Waterman, M. L. (2012/2012). TCF/LEFs and Wnt Signaling in the Nucleus. Cold Spring Harbor Perspect. Biol. 4, a007906. doi:10.1101/cshperspect.a007906

Cao, Z.-Q., Wang, Z., and Leng, P. (2019). Aberrant N-Cadherin Expression in Cancer. Biomed. Pharmacother. 118, 109320. doi:10.1016/j.biopha.2019.109320

Cappiello, N., D’Angeli, F., Cambria, M. T., Candido, S., Guallongo, C., Salmeri, M., et al. (2019). Pericytes in Microvessels: From ’Mural’ Function to Brain and Retina Regeneration. IJMS 20, 6351. doi:10.3390/ijms20246351

Caruso, R. A., Fedele, F., Finocchiaro, G., Pizzi, G., Nunnari, M., Gitto, G., et al. (2009). Ultrastructural Descriptions of Pericyte/endothelium Peg-Socket Interdigitations in the Microvasculature of Human Gastric Carcinomas. Anticancer Res. 29, 449–453.

Chanda, D., Otuopalova, E., Smith, S. R., Volckaert, T., De Langhe, S. P., and Thannickal, V. J. (2019). Developmental Pathways in the Pathogenesis of Lung Fibrosis. Mol. Aspects Med. 65, 56–69. doi:10.1016/j.mam.2018.08.004

Charras, G., and Yap, A. S. (2018). Tensile Forces and Mechanotransduction at Cell-Cell Junctions. Curr. Biol. 28, R445–R457. doi:10.1016/j.cub.2018.02.003

Cheng, S.-L., Lechman, E. D., Warlow, P. M., Zhang, S.-F., Zhang, L., et al. (1998). Human Osteoblasts Express a Repertoire of Cadherins, Which Are Critical for BMP-2-Induced Osteogenic Differentiation. J. Bone Miner. Res. 13, 633–644. doi:10.1059/jbmr.1998.13.643

Chua, M. L., David, S., and Blaschuk, O. (1991). Differentiation and Survival of Rat Olfactory Epithelial Neurons in Dissociated Cell Culture. Develop. Brain Res. 60, 123–132. doi:10.1016/0165-3806(91)90040-p

Colak-Algara, N., and Millán, J. (2019). How many Cadherins Do Human Endothelial Cells Express? Cell. Mol. Life Sci. 76, 1299–1317. doi:10.1007/s00018-018-2991-9

Correa-Gallegos, D., Jiang, D., Christ, S., Ramesh, P., Ye, H., Wannemacher, J., et al. (2019). Patch Repair of Deep Wounds by Mobilized Fascia. Nature 576, 287–292. doi:10.1038/s41586-019-1794-y

Cosgrove, B. D., Mui, K. L., Driscoll, T. P., Caliari, S. R., Mehta, K. D., Assoian, R. K., et al. (2016). N-cadherin Adhesive Interactions Modulate Matrix

**AUTHOR CONTRIBUTIONS**

OB is the sole author of this review article.

Blaschuk, O. W., and Devemey, E. (2009). Cadherins as Novel Targets for Anti-cancer Therapy. Eur. J. Pharmacol. 625, 195–1988. doi:10.1016/j.ejphar.2009.05.033

Blaschuk, O. W. (2015). N-cadherin Antagonists as Oncology Therapeutics. Phil. Trans. R. Soc. B 370, 20140039. doi:10.1098/rspb.2014.0039

Blaschuk, O. W., Pouliot, Y., and Holland, P. C. (1990a). Identification of a Conserved Region Common to Cadherins and Influenza Strain A Hemagglutinins. J. Mol. Biol. 211, 679–682. doi:10.1002/2836-90065-1

Blaschuk, O. W., and Rowlands, T. M. (2000). Cadherins as Modulators of Angiogenesis and the Structural Integrity of Blood Vessels. Cancer Metastasis Rev. 19, 1–5. doi:10.1026/102652216059

Blaschuk, O. W., and Rowlands, T. M. (2006). “Cadherin Antagonists as Vasculature-Targeting Agents,” in Vascular-targeted Therapies in Oncology. Editor D. W. Siemann (Hoboken NJ: John Wiley & Sons), 195–204. doi:10.002/0470035439.ch11

Blaschuk, O. W., Sullivan, R., David, S., and Pouliot, Y. (1990b). Identification of a Cadherin Cell Adhesion Recognition Sequence. Devol. Biol. 139, 227–229. doi:10.1016/0012-1606(90)90290-y

Brasch, J., Harrison, O. J., Ahlsen, G., Carnally, S. M., Henderson, R. M., Honig, B., et al. (2011). Structure and Binding Mechanism of Vascular Endothelial Cadherin: a Divergent Classical Cadherin. J. Mol. Biol. 408, 57–73. doi:10.1016/j.jmb.2011.01.031

Brasch, J., Katsamba, P. S., Harrison, O. J., Ahlsen, G., Troyanovsky, R. B., Indra, L., et al. (2018). Homophilic and Heterophilic Interactions of Type II Cadherins Identify Specificity Groups Underlying Cell-Adhesive Behavior. Cell Rep. 23, 1840–1852. doi:10.1016/j.celrep.2018.04.012

Bushy, S., Garg, S., Junek, S., Vogel, D., Ansari, N., Stelzer, E. H. K., et al. (2013). Role of N-Cadherin Cis and Trans Interfaces in the Dynamics of Adherens Junctions in Living Cells. PLoS ONE 8, e81517. doi:10.1371/journal.pone.0081517
Valenta, T., Hausmann, G., and Basler, K. (2012). The many Faces and Functions of β-catenin. *EMBO J.* 31, 2714–2736. doi:10.1038/emboj.2012.150

Vendome, J., Felsowaly, K., Song, H., Yang, Z., Jin, X., Brasch, J., et al. (2014). Structural and Energetic Determinants of Adhesive Binding Specificity in Type I Cadherins. *Proc. Natl. Acad. Sci. USA* 111 (111), E4175–E4184. doi:10.1073/pnas.1416737111

Vite, A., and Radice, G. L. (2014). N-cadherin/catenin Complex as a Master Regulator of Intercalated Disc Function. *Cell Commun. Adhes.* 21, 169–179. doi:10.3109/15419061.2014.908853

Volk, T., Cohen, O., and Geiger, B. (1987). Formation of Heterotypic Adherens-type Junctions between L-CAM-Containing Liver Cells and A-CAM-Containing Lens Cells. *Cell* 50, 987–994. doi:10.1016/0092-8674(87)90525-3

Volk, T., and Geiger, B. (1986b). A-CAM: a 135-kD Receptor of Intercellular Adherens Junctions. II. Antibody-Mediated Modulation of junction Formation. *J. Cell Biol.* 103, 1451–1464. doi:10.1083/jcb.103.4.1451

Volk, T., and Geiger, B. (1986a). A-CAM: a 135-kD Receptor of Intercellular Adherens Junctions. I. Immunoelectron Microscopic Localization and Biochemical Studies. *J. Cell Biol.* 103, 1441–1450. doi:10.1083/jcb.103.4.1441

Wadey, K., Lopes, J., Bendek, M., and George, S. (2018). Role of Smooth Muscle Cells in Coronary Artery Bypass Grafting Failure. *Cardiovase. Res.* 114, 601–610. doi:10.1093/cvr/cvy021

Wilby, M. J., Muir, E. M., Fok-Seang, J., Gour, B. J., Blaschuk, O. W., and Favcett, J. W. (1999). N-cadherin Inhibits Schwann Cell Migration on Astrocytes. *Mol. Cell Neurosci.* 14, 66–84. doi:10.1006/mcne.1999.0766

Williams, E., Williams, G., Gour, B. J., Blaschuk, O. W., and Doherty, P. (2000). A Novel Family of Cyclic Peptide Antagonists Suggests that N-Cadherin Specificity Is Determined by Amino Acids that Flank the HAV Motif. *J. Biol. Chem.* 275, 4007–4012. doi:10.1074/jbc.275.6.4007

Williams, G., Williams, E.-J., and Doherty, P. (2002). Dimeric Versions of Two Short N-Cadherin Binding Motifs (HAVDI and INPISG) Function as N-Cadherin Agonists. *J. Biol. Chem.* 277, 4361–4367. doi:10.1074/jbc.M109185200

Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. 1., and Werb, Z. (2020). Concepts of Extracellular Matrix Remodelling in Tumour Progression and Metastasis. *Nat. Commun.* 11, 5120. doi:10.1038/s41467-020-18794-x

Yang, S., Jin, H., Zhu, Y., Wan, Y., Opoku, E. N., Zhu, L., et al. (2017). Diverse Functions and Mechanisms of Pericytes in Ischemic Stroke. *Cn* 15, 892–905. doi:10.1074/jbc.M117.815666

Yang, X., and Lee, S. H. (2016). Identification of ESE1 as a β-Catenin Binding Protein. *Anticancer Res.* 36, 2697–2703.

Yarom, N., Stewart, D., Avruch, L., Malik, R., Wells, J., and Jonker, D. J. (2011). ADH-1 in the Treatment of Metastatic Adrenocortical Carcinoma-Ccase Report. *Anticancer Res.* 31, 3921–3925.

Yarom, N., Stewart, D., Malik, R., Wells, J., Avruch, L., and J. Jonker, D. (2013). Phase I Clinical Trial of Exherin (ADH-1) in Patients with Advanced Solid Tumors. *Cep 8*, 81–88. doi:10.2174/157488471308010011

Zhang, Y., Qin, Z., Qu, Z. Z., Ge, M., and Yang, J. (2020). Cadherin-based Biomaterials: Inducing Stem Cell Fate towards Tissue Construction and Therapeutics. *Prog. Nat. Sci. Mater. Int.* 30, 597–608. doi:10.1016/j.pnsci.2020.09.001

Zhu, M., Zhong, W., Cao, W., Zhang, Q., and Wu, G. (2022). Chondroinductive/chondroconductive Peptides and Their-Functionalized Biomaterials for Cartilage Tissue Engineering. *Bioactive Mater.* 9, 221–238. doi:10.1016/j.bioactmat.2021.07.004

Conflict of Interest: OB have equity in Zonula Inc. This company owns the patent on “compound 15”.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Blaschuk. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.